|Bid||19.25 x 0|
|Ask||19.27 x 0|
|Day's Range||19.08 - 19.28|
|52 Week Range||12.65 - 20.75|
|Beta (3Y Monthly)||0.49|
|PE Ratio (TTM)||68.79|
|Forward Dividend & Yield||0.23 (1.18%)|
|1y Target Est||12.43|
Mick Farrell, ResMed CEO, joined Yahoo Finance from the New York Stock Exchange as the company celebrates its 20th year as a publicly traded company.
The survey highlights a reason for optimism that the markets for digital health technology will only continue to grow. The survey of a nationally representative sample of 3,000 Americans, conducted in partnership with Edelman Intelligence, revealed that the use of – and confidence in – remote digital health technology is widespread: 56% of those surveyed currently monitor their health with at least one digital data collection tool. Perhaps more surprising, remote digital health technology seems to have deepened people’s connection with their physicians rather than distanced them from one another.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of June 28. The results of that effort will be put on display in this article, as […]
Cerner Corporation (CERN), a global health platform and innovation company, and ResMed (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced a new collaboration agreement to help providers make more informed treatment decisions, control costs and deliver seamless care across health systems to the home. To address this trend, Cerner designated ResMed’s Brightree Home Health and Hospice platform as its preferred solution in the space to integrate with its Cerner Millennium® electronic health record (EHR).
ResMed today announced it plans to release financial and operational results for the first quarter of fiscal year 2020 on Thursday, October 24, 2019, after the New York Stock Exchange closes.
With more than 10 million cloud-connected CPAP and other breathing devices on the market, CEO Mick Farrell completely understands why patients are wary about letting those devices send data to the cloud.
ResMed (NYSE: RMD, ASX: RMD) today announced that CEO Mick Farrell will ring The Opening Bell® at the New York Stock Exchange (NYSE) on Monday, September 30, 2019 at 9:30 a.m. ET. Farrell will be joined on the bell podium with other members of the ResMed management team to celebrate 20 years of being listed on the NYSE and to commemorate ResMed’s 30th anniversary. Founded in 1989, ResMed began as ResCare, a management buy-out of sleep apnea technology from Baxter Healthcare.
CEO of Resmed Inc (30-Year Financial, Insider Trades) Michael J. Farrell (insider trades) sold 6,651 shares of RMD on 09/09/2019 at an average price of $137.38 a share. Continue reading...
ResMed Inc (RMD) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. ResMed Inc is a part of the healthcare sector. Continue reading...
President and COO ResMed Inc. of Resmed Inc (30-Year Financial, Insider Trades) Robert Andrew Douglas (insider trades) sold 4,111 shares of RMD on 07/15/2019 at an average price of $124.5 a share. Continue reading...
MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
CEO of Resmed Inc (NYSE:RMD) Michael J. Farrell sold 6,651 shares of RMD on 07/08/2019 at an average price of $123.76 a share.